研究合併E1A基因和表皮生長因子受體酪氨酸激?抑制劑在三重陰性乳癌臨床前治療的嶄新策略(3/3)

Medicine & Life Sciences

1. Adenoviridae 6%
2. Breast 5%
3. Cell Line 8%
4. Drug Development 6%
5. ErbB Receptors 72%
6. Estrogen Receptor alpha 8%
7. Genetic Therapy 12%
8. Head 5%
9. human ERBB2 protein 8%
10. Neck 5%
11. Pharmaceutical Preparations 5%
12. Progesterone Receptors 7%
13. Protein-Tyrosine Kinases 12%
14. Receptor Protein-Tyrosine Kinases 7%
15. Signal Transduction 5%
16. Therapeutics 7%
17. Triple Negative Breast Neoplasms 100%